Generics BulletinAmgen remains confident in the commercial and clinical potential of its intravenous biosimilar programs for immuno-oncology agents such as its ABP 234 biosimilar to Keytruda (pembrolizumab) and ABP 20
ScripAmgen reported double-digit sales growth for more than a dozen of its products in the second quarter and talked about plans for expanding its use of artificial intelligence. But CEO Robert Bradway sai
Pink SheetUS President Donald Trump appears to be giving the drug industry more time to voluntarily come up with ways to bring American drug prices more in line with those paid by other wealthy nations, a sign
In VivoPharma’s AI moment has arrived—not as a futuristic vision, but as a pragmatic engine of operational and scientific change. To understand how biopharma companies are navigating this shift, Define Ventu